Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy

• Published in: PloS one 2017-08, Vol.12 (8), p.e0182739-e0182739
• Main Authors: Lucas, Julie L, Tacheny, Erin A, Ferris, Allison, Galusha, Michelle, Srivastava, Apurva K, Ganguly, Aniruddha, Williams, P Mickey, Sachs, Michael C, Thurin, Magdalena, Tricoli, James V, Ricker, Winnie, Gildersleeve, Jeffrey C
• Format: Article
• Language: English
• Subjects: Analysis; Antigens; Assaying; Biology and Life Sciences; Biomarkers; Biomarkers - metabolism; Blood group A; Blood groups; Cancer; Cancer therapies; Cancer treatment; Cancer Vaccines - therapeutic use; Carbohydrates; Chemical vapor synthesis; Clinical trials; Glycan; Health care; Health care reform; Humans; Immunoglobulin M; Immunoglobulin M - blood; Immunoglobulins; Immunologic Tests - methods; Immunotherapy; Laboratories; Laboratory diagnosis; Ligands; Male; Medical diagnosis; Medical prognosis; Medical research; Medicin och hälsovetenskap; Medicine and Health Sciences; Oligosaccharides - immunology; Patients; Polysaccharides - metabolism; Prostate cancer; Prostatic Neoplasms - immunology; Prostatic Neoplasms - therapy; Protein Array Analysis; Reproducibility; Research and Analysis Methods; Serum levels; Side effects; Survival; Survival Analysis; Therapy; Toxicity; Treatment Outcome; Vaccines
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0182739

Cancer therapies can provide substantially improved survival in some patients while other seemingly similar patients receive little or no benefit. Strategies to identify patients likely to respond well to a given therapy could significantly improve health care outcomes by maximizing clinical benefits while reducing toxicities and adverse effects. Using a glycan microarray assay, we recently reported that pretreatment serum levels of IgM specific to blood group A trisaccharide (BG-Atri) correlate positively with overall survival of cancer patients on PROSTVAC-VF therapy. The results suggested anti-BG-Atri IgM measured prior to treatment could serve as a biomarker for identifying patients likely to benefit from PROSTVAC-VF. For continued development and clinical application of serum IgM specific to BG-Atri as a predictive biomarker, a clinical assay was needed. In this study, we developed and validated a Luminex-based clinical assay for measuring serum IgM specific to BG-Atri. IgM levels were measured with the Luminex assay and compared to levels measured using the microarray for 126 healthy individuals and 77 prostate cancer patients. This assay provided reproducible and consistent results with low %CVs, and tolerance ranges were established for the assay. IgM levels measured using the Luminex assay were found to be highly correlated to the microarray results with R values of 0.93-0.95. This assay is a Laboratory Developed Test (LDT) and is suitable for evaluating thousands of serum samples in CLIA certified laboratories that have validated the assay. In addition, the study demonstrates that discoveries made using neoglycoprotein-based microarrays can be readily migrated to a clinical assay.